Physician profile
Philip Jiang
NPI 1487179354
$3,059.36
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $266 · 2021: $778 · 2022: $1,448 · 2023: $551 · 2024: $16.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $567.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $813.92 | 2020-2024 | Collagenase Santyl, Regranex |
| Treace Medical Concepts, INC. | $732.90 | 2022 | |
| Bioventus LLC | $559.50 | 2021-2023 | |
| Misonix INC | $219.18 | 2020-2021 | |
| Kci USA, INC. | $215.89 | 2022-2023 | V.A.C. Veraflo, V.A.C. Dermatac |
| Organogenesis INC. | $182.83 | 2020-2022 | |
| Advanced Oxygen Therapy INC. | $90.82 | 2022 | |
| Depuy Synthes Sales INC. | $53.99 | 2022 | |
| Integra Lifesciences Corporation | $50.24 | 2020 | |
| Stryker Corporation | $42.92 | 2022 | |
| Musculoskeletal Transplant Foundation INC. | $38.18 | 2021 | |
| Heron Therapeutics, INC. | $22.22 | 2021 | |
| Kerecis Limited | $15.59 | 2021 | |
| Paratek Pharmaceuticals, INC. | $13.58 | 2022 | |
| Reprise Biomedical, INC. | $7.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Jiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.